Targeting the AMPK Pathway with Natural Products for Heart Failure: A Systematic Review of Preclinical Evidence
1Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
Insights
Traditional Chinese Medicine (TCM) shows potential for heart failure (HF) by modulating AMP-activated protein kinase (AMPK). However, current preclinical evidence is mostly preliminary, requiring further validation for clinical application.
Area of Science:
- Cardiology
- Pharmacology
- Integrative Medicine
Background:
- Heart failure (HF) is a major global health concern.
- AMP-activated protein kinase (AMPK) plays a critical role in energy homeostasis and is implicated in HF.
- Traditional Chinese Medicine (TCM) is explored for HF, but evidence on its AMPK modulation needs synthesis.
Purpose of the Study:
- To systematically review preclinical evidence on TCM's effects on AMPK in heart failure.
- To assess the quality and level of evidence for TCM-mediated AMPK modulation in HF models.
Main Methods:
- Comprehensive literature search of PubMed and Web of Science (Jan 2020-Dec 2025).
- Inclusion of original research on TCM compounds/formulas in HF models with AMPK modulation data.
- Assessment of study quality and evidence levels following PRISMA 2020 guidelines.
Main Results:
- 56 studies met inclusion criteria, revealing limited direct evidence for AMPK-dependent cardioprotection.
- Cinnamaldehyde and paeoniflorin showed robust validation; berberine, crocin, ginsenoside Rb1, and honokiol demonstrated pathway-specific effects.
- Most complex herbal formulas provided correlative evidence, with Fuyu Decoction as a notable exception.
Conclusions:
- Preclinical evidence for TCM-mediated AMPK modulation in HF is largely preliminary and correlative.
- Further research is needed to validate causality using genetic models and human-relevant systems.
- Targeted investigation of specific TCM compounds and rigorous validation are crucial for clinical translation.
Abstract:
Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. AMP-activated protein kinase (AMPK) is a central regulator of energy homeostasis, and its dysregulation is implicated in HF pathophysiology. Traditional Chinese Medicine (TCM) has been investigated in HF management, but a systematic synthesis of preclinical evidence on TCM-mediated AMPK modulation is lacking. Methods: PubMed and Web of Science were searched from January 2020 to December 2025 using a comprehensive strategy combining terms for AMPK, HF, and TCM. Studies were included if they were original research investigating TCM-derived compounds or formulas in HF models and reporting AMPK modulation. Study quality and evidence levels were assessed using predefined criteria. The review was conducted in accordance with PRISMA 2020 guidelines. Results: Of 243 records identified, 56 studies met the inclusion criteria (7 from database search and 49 from manual screening). Direct evidence for AMPK-dependent cardioprotection was limited. Cinnamaldehyde and paeoniflorin showed the most rigorous validation with confirmed target engagement and loss-of-function rescue. Berberine, crocin, ginsenoside Rb1, and honokiol demonstrated pathway-specific effects validated by pharmacological or genetic approaches. Most complex herbal formulas provided correlative evidence only, with Fuyu Decoction being a notable exception where AMPK agonist EX229 confirmed pathway involvement. Conclusions: Current evidence for TCM-mediated AMPK modulation in HF remains predominantly preliminary and correlative. Future research should prioritize causality validation using genetic models and human-relevant systems.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:29Cardiomyopathy V: Interprofessional Care